MEC 20th Annual Miami Cancer Meeting 2024

• Start: 19 January 2024
• End: 21 January 2024
• Venue: The Westin Tampa Waterside Hotel

Conference Description

MEC 20th Annual Miami Cancer Meeting 2024 The areas of focus for this conference will include the current standards of care in the treatment of the aforementioned malignancies and new developments in theSe areas of Cancer care. There Will be much emphasis on molecular diagnosis and individualization of cancer therapy based on molecular profiles.

There will be reviews of new chemOtherapeutic, antiangiogenic, and immUnotherapeutic agents. Topics in solid tumors and hematological malignancies will be reviewed and will include tepics in breast cancer, lung cancer, gastrointestinal (GI) malignancies, gynecologic malignancies, genitourinary (GU) cancers head and neck cancers, melanoma, and hematological malignancies such as multiple myeloma, CLL and non-Hodgkin’s-lymphoma. There will also be a special session devoted to toxicity profiles, sUpportive care, and challenges in cancer therapy.

Presentations from the latest national (AACR, ASCO, SABC, and ASH) and international forums (ESMO and WCLC) meetings Will be discussed and guidelines of cancer care using a team approach will be emphasized. The participants in the conference will have the opportunity not only to learn, review,- and understand the state-of-the-art‘ management in cancer care using a team approach but also engage in personal interaction with our panel of exports in these subjects during the questions and answers sessions.

This 3-day conference is designed for medical oncologists, hematologists, radiation oncologists, surgical oncologists, physician associates (PA), advanced registered nurse practitioners (ARNP), oncology nurses, registered pharmacists, pharmacy technicians, and radiation therapists. General practitioners will have the benefit of reviewing standard care and new developments in cancer management. Residents in training and fellows from these, specialties are encouraged to attend.

+ Include: 26 videos + 1 pdf, size: 3.31 GB

+ Topics:

• Acute Myeloid Leukemia.mp4
  B-Cell NHL (Aggressive) – Relapsed (CAR T versus Bispecifics).mp4
  B-Cell NHL (Low-Grades).mp4
  Bi-Specific Inhibitor & ADC in Lung Cancer.mp4
  Challenges in Targeting Head and Neck Squamous Cell Carcinoma.mp4
  Chronic Lymphocytic Leukemia.mp4
  Controversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant & Post-neoadjuvant Therapies (Part 1).mp4
  Controversies in Breast Cancer Use of ctDNA to Tailor Systemic Adjuvant & Post-neoadjuvant Therapies (Part 2).mp4
  Controversies in Lung Cancer Neoadjuvant vs Adjuvant IO in Early Stage NSCLC.mp4
  Endocrine Therapy for Early -and Late- Stages Breast Cancer Therapeutic Updates.mp4
  Flyer.pdf
  Front Line Targeted Therapy in NSCLC Tyrosine Kinase Inhibitors.mp4
  HER-2 Disease Amplification, Overexpression, Mutation in Breast Cancer.mp4
  How to Handle Myelotoxicity from Chemotherapy in 2024 From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection.mp4
  Immunotherapy in Breast Cancer Now & The Future.mp4
  Immunotherapy in NSCLC First Line for Advanced Disease.mp4
  Kidney & Bladder Cancer Targeted, Immuno & Other Strategies.mp4
  Management of Malignant Hypercalcemia, Bone Metastases & Standard Precautions to Decrease Adverse Events.mp4
  Myelodysplasia De Novo and Acquired- What To Do.mp4
  New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue.mp4
  Novel Advances in Multiple Myeloma as Front-Line Therapy.mp4
  Prostate Cancer Diagnostic and Therapeutic Updates.mp4
  Small Cell Lung Cancer.mp4
  Targeted Therapy and Immunotherapy for Soft Tissue Tissue Sarcomas.mp4
  Triple Negative Breast Cancer Optimal Strategies.mp4
  Updates in Waldenstroms Macroglobulinemia.mp4
  What To Do When Patients Getting Immunotherapy Do Not Respond to Steroids (Hepatitis, Colitis, Pneumonitis, and Others).mp4